Lotus Eye Hospital and Institute Limited (LOTUSEYE) Fair Value & Analysis
Healthcare · IN · Market cap ₹2.6B
Fair value as of: Jul 3, 2026
From 12 valuation models · updated today
Share price +16.4% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹71.87 – ₹141.38 · fair‑value band ₹61.04 – ₹101.10 · the ₹128.13 price screens above the ₹81.07 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Lotus Eye Hospital and Institute Limited (LOTUSEYE) currently trades at ₹128.13, while our model-based Fair Value estimate is ₹81.07 — implying the stock looks roughly 36.7% overvalued today. We read business quality at 60/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, Lotus Eye Hospital and Institute Limited generated revenue of ₹537M at a net margin of 0.2%. Revenue grew 18.2% year over year. It earns a return on equity of 0.1%. Net debt stands at ₹120M. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Lotus Eye Hospital and Institute Limited, a specialty eye care hospital, provides eye care and related services in India. The company offers ReLEx SMILE, a refractive lenticule extraction small incision lenticule extraction; touch free laser; lasik eye surgery; Epi-LASIK, an epithelial laser in situ keratomileusis; Intralase, a blade-free technique to create the corneal flap; Zyoptix Supracor laser technology; robotic femto laser cataract surgery; phacoemulsification; paediatric eye care and squint surgery; and micro incision cataract surgery treatments. It provides treatment services for various eye problems, such as refractive, cataract, glaucoma, retinal disease/diabetic eye care, neuro ophthalmology, binocular vision, and cornea infections, as well as various eye related courses. The company was formerly known as Lotus Eye Care Hospital Limited and changed its name to Lotus Eye Hospital and Institute Limited in April 2013. Lotus Eye Hospital and Institute Limited was founded in …
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Lotus Eye Hospital and Institute Limited reported revenue of ₹537M in FY2026 versus ₹389M in FY2022, a compound +8.4%/yr. Reported net income was ₹804K in FY2026, compounding −59.5%/yr from FY2022.
Is LOTUSEYE fairly valued? → Check now
Similar stocks
6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc H1CA34 | R$96.00 | R$25.67 | -73% |
| Fresenius SE FSNUY | $11.27 | $8.25 | -27% |
| Q0F Q0F | 2.76 SGD | 1.28 SGD | -54% |
| 5225 5225 | 8.70 MYR | 2.61 MYR | -70% |
| IHHHF IHHHF | $1.71 | $1.26 | -26% |
| Rede D'Or São Luiz S.A RDOR3 | R$33.83 | R$46.94 | +39% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Lotus Eye Hospital and Institute Limited (LOTUSEYE) undervalued?
What is the fair value of LOTUSEYE?
What is the quality score of LOTUSEYE?
What is the revenue of Lotus Eye Hospital and Institute Limited (LOTUSEYE)?
What is the net profit margin of LOTUSEYE?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.